Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1263-1270

  Witzig, Thomas E ^a   White, Christine A ^a   Gordon, Leo I ^a   Wiseman, Gregory A ^a   Emmanouilides, Christos ^a   Murray, James L ^a   Lister, John ^a   Multani, Pratik S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY;

ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER RELAPSE; CONTROLLED STUDY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; MYELOID LEUKEMIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; AGE; AGED; B CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; IMMUNOLOGY; INFECTION; MALE; MIDDLE AGED; MORTALITY; SAFETY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFECTION; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEUTROPENIA; RADIOIMMUNOTHERAPY; SAFETY;

EID: 0038175332     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.043     Document Type: Article

References (26)

1. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Hainsworth JD, Burris HA, Morrisey LH: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 95:3052-3056, 2000
3. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
4. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
5. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
6. Witzig TE, White CA, Flinn IW, et al: Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma. Blood 96:507a, 2000 (abstr 2183)
7. Witzig TE, Gordon LI, Wiseman GA, et al: Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell non-Hodgkin's lymphoma (L/F/T NHL) and mild thrombocytopenia. Blood 96:728a, 2000 (abstr 3149)
8. Chinn PC, Morena RA, Wiseman GA, et al: Clinical experience with preparation of Zevalin (ibritumomab tiuxetan, IDEC-Y2B8/IDEC-In2B8) using a radiolabeled kit. Eur J Nucl Med 27:1163, 2000 (abstr)
9. Wiseman GA, White CA, Sparks RB, et al: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-194, 2001
10. Witzig TE, White CA, Gordon LI, et al: Reduced-dose Zevalin radioimmunotherapy for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) patients with pre-existing thrombocytopenia: report of interim results of a phase II trial. Blood 94:92a, 1999 (abstr 400)
11. Witzig TE, White CA, Gordon L, et al: Response to Zevalin is superior to response to rituximab regardless of age and extent of disease. Proc Am Soc Clin Oncol 20:279a, 2001 (abstr 1115)
12. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
13. Pedersen-Bjergaard J, Andersen MK, Christiansen DH: Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273-3279, 2000
14. Kantarjian HM, Keating MJ: Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14:435-443, 1987
15. Travis LB, Curtis RE, Boice JD Jr, et al: Second cancers following non-Hodgkin's lymphoma. Cancer 67:2002-2009, 1991
16. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457, 1994
17. Pedersen-Bjergaard J, Andersen MK: Secondary or therapy-related MDS and AML and their chromosome aberrations: Important to study but difficult to establish causality. Haematologica 83:481-482, 1998
18. Kyle RA, Greipp PR, Gertz MA, et al: Waldenstrom's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000
19. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 103:195-200, 1985
20. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
21. Berger AM, Clark-Snow RA, Rosenberg SA: Adverse effects of treatment: Nausea and vomiting, in DeVita VT Jr, Hellman S, et al (eds): Cancer, Principles and Practice of Oncology (ed 5). Philadelphia, PA, JB Lipincott Co, 1997, pp 2705-2714
22. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94:297-312, 1993
23. DeNardo SJ, DeNardo GL, Kukis DL, et al: 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 40:302-310, 1999
24. Kaminski MS, Press OW, Lister TA, et al: Iodine I 131 tositumomab for patients with small lymphocytic lymphoma (SLL): Overall clinical trial experience. Blood 94:88a, 1999 (abstr 386)
25. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
26. 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 38:91-101, 2000